Sugi Predict

Sugi Predict / Compounds / SCHEMBL1760643

SCHEMBL1760643

SCHEMBL1760643

COC(=O)C1Cc2cc(OC)ccc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MTNR1A P48039 3/20 0.43
▸ MTNR1B P49286 1/20 0.43
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ ACHE P22303 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ROCK2 O75116 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HSPA1A P0DMV8 1/20 0.39
▸ PTPN7 P35236 1/20 0.39
▸ DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567814 1.00 ALDH1A1 (0.44) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL7286562 1.00 ALDH1A1 (0.44) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL4999513 0.90 MTNR1A (0.44) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL28634734 0.90 MTNR1A (0.44) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL4365304 0.87 GAA (0.55) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL7037302 0.87 GAA (0.55) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL7044783 0.87 GAA (0.55) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL3250596 0.86 ALOX15 (0.43) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL7335768 0.86 ALDH1A1 (0.51) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2
SCHEMBL30358032 0.86 ALDH1A1 (0.51) ALDH1A1TP53CYP1A2HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329324-B2 Indoline compounds as granzyme B inhibitors viDA Therapeutics (CA) 2019-06-25 — — US disclosed
US-20180057528-A1 INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS VIDA THERAPEUTICS INC. (CA) 2018-03-01 — — US disclosed
US-9605021-B2 Indoline compounds as granzyme B inhibitors VIDA THERAPEUTICS INC. (CA) 2017-03-28 — — US disclosed
US-20160083422-A1 INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS VIDA THERAPEUTICS INC. (CA) 2016-03-24 — — US disclosed
WO-2015131100-A1 LIGAND-CONTROLLED C(SP3)-H ARYLATION AND OLEFINATION IN SYNTHESIS OF UNNATURAL CHIRAL ALPHA AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2015-09-03 — — WO disclosed
WO-2014153667-A1 COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS VIDA THERAPEUTICS, INC. (CA) 2014-10-02 — — WO disclosed
WO-2014153666-A1 INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS VIDA THERAPEUTICS, INC. (CA) 2014-10-02 — — WO disclosed
US-8247432-B2 Tripeptidyl peptidase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-21 — — US disclosed
US-20110224255-A1 TRIPEPTIDYL PEPTIDASE INHIBITORS BRESLIN HENRY JOSEPH 2011-09-15 — — US disclosed
US-7947713-B2 (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-24 — — US disclosed
EP-1392291-B1 TRIPEPTIDYL PEPTIDASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2007-05-30 — — EP disclosed
US-20060276509-A1 Tripeptidyl peptidase inhibitors BRESLIN HENRY J 2006-12-07 — — US disclosed
US-7125891-B2 Tripeptidyl peptidase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-10-24 — — US disclosed
EP-1392291-A2 TRIPEPTIDYL PEPTIDASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-03-03 — — EP disclosed
US-20040034089-A1 Tripeptidyl peptidase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-19 — — US disclosed
WO-2002036116-A9 TRIPEPTIDYL PEPTIDASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2003-05-30 — — WO disclosed
WO-2002036116-A2 TRIPEPTIDYL PEPTIDASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2002-05-10 — — WO disclosed
US-6359138-B1 CENTRAL NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2002-03-19 — — US disclosed
EP-0846683-B1 4-Hydroxy-piperidine derivatives HOFFMANN LA ROCHE (CH) 2001-09-19 — — EP disclosed
EP-0846683-A1 4-Hydroxy-piperidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034089-A1 Tripeptidyl peptidase inhibitors CCKAR, CCKBR, VIP ALDH1A1 2290/4885TP53 4834/4885CYP1A2 1930/4885
US-20180057528-A1 INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS GZMB, PRF1, CTSB ALDH1A1 4826/4885TP53 36/4885CYP1A2 3751/4885
US-10329324-B2 Indoline compounds as granzyme B inhibitors GZMB, PRF1, CTSB ALDH1A1 4826/4885TP53 36/4885CYP1A2 3751/4885
US-20160083422-A1 INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS GZMB, PRF1, CTSB ALDH1A1 4826/4885TP53 36/4885CYP1A2 3751/4885
US-20110224255-A1 TRIPEPTIDYL PEPTIDASE INHIBITORS CCKAR, CCKBR, VIP ALDH1A1 3045/4885TP53 4662/4885CYP1A2 2320/4885
US-20060276509-A1 Tripeptidyl peptidase inhibitors CCKAR, CCKBR, VIP ALDH1A1 3045/4885TP53 4662/4885CYP1A2 2320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.